Hansa Biopharma Debt 2024

Hansa Biopharma Aktienanalyse

What does Hansa Biopharma do?

Hansa Biopharma AB is a Swedish biotechnology company specializing in the development of therapy options for rare immune and inflammatory diseases. The company was founded in Lund in 1986 and now has branches in the USA and Japan. The company's business model and divisions include clinical development, corporate development, and production. The clinical development division focuses on conducting clinical studies to demonstrate the effectiveness and safety of new drugs. The corporate development division handles collaboration with regulatory authorities, investors, and other partners. The production division encompasses the manufacturing of products developed by Hansa Biopharma AB. The company's products include Idefirix, an antibody-based drug candidate for the treatment of severe hemolysis due to alloimmune blood group antibodies, and an immunoglobulin production technology platform for the development of antibody therapies for various diseases. Hansa Biopharma AB's roots date back to 1986 when it was established as a spin-off from Lund University. Initially, the company focused on the development and production of diagnostics and reagents for immunology and clinical chemistry. In recent years, it shifted its focus to developing innovative therapies for rare immune and inflammatory diseases. In 2010, the company made a breakthrough with the discovery of the 174H target, which led to the development of Idefirix. Idefirix has since successfully completed phase III clinical trials and may soon be approved for the treatment of severe hemolysis. In conclusion, Hansa Biopharma AB is a leading biotechnology company with a strong vision and clear strategy for developing innovative therapies for rare immune and inflammatory diseases. The company specializes in antibody therapies and is currently focused on the development of Idefirix and the expansion of its immunoglobulin production technology platform. With a strong research pipeline and experienced management team, Hansa Biopharma AB is well-positioned to make significant progress in the coming years and develop innovative therapies for patients with rare diseases. Hansa Biopharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Debt Details

Understanding Hansa Biopharma's Debt Structure

Hansa Biopharma's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Hansa Biopharma's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Hansa Biopharma’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Hansa Biopharma’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Hansa Biopharma Stock

What is the debt of Hansa Biopharma this year?

Hansa Biopharma has a debt level of 134.71 SEK this year.

What was the debt of Hansa Biopharma compared to the previous year?

The debt of Hansa Biopharma has increased by -106.12% compared to the previous year dropped.

What are the consequences of high debt for investors in Hansa Biopharma?

High debt can pose a risk for investors of Hansa Biopharma, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.

What are the consequences of low debt for investors of Hansa Biopharma?

Low debt means that Hansa Biopharma has a strong financial position and is able to fulfill its obligations without overburdening its finances.

How does an increase in debt from Hansa Biopharma affect the company?

An increase in debt of Hansa Biopharma can adversely affect the financial condition of the company and result in a higher burden on its finances.

How does a reduction of debt of Hansa Biopharma affect the company?

A reduction in debt of Hansa Biopharma can strengthen the company's financial position and improve its ability to meet its financial obligations.

What are some factors that influence the debt of Hansa Biopharma?

Some factors that can influence the debt of Hansa Biopharma include investments, acquisitions, operating costs, and revenue development.

Why are the debts of Hansa Biopharma so important for investors?

The debts of Hansa Biopharma are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.

What strategic measures can Hansa Biopharma take to change the debt?

To change the debt, Hansa Biopharma can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.

How much dividend does Hansa Biopharma pay?

Over the past 12 months, Hansa Biopharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Hansa Biopharma is expected to pay a dividend of 0 SEK.

What is the dividend yield of Hansa Biopharma?

The current dividend yield of Hansa Biopharma is .

When does Hansa Biopharma pay dividends?

Hansa Biopharma pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Hansa Biopharma?

Hansa Biopharma paid dividends every year for the past 0 years.

What is the dividend of Hansa Biopharma?

For the upcoming 12 months, dividends amounting to 0 SEK are expected. This corresponds to a dividend yield of 0 %.

In which sector is Hansa Biopharma located?

Hansa Biopharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von Hansa Biopharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Hansa Biopharma from 6/19/2024 amounting to 0 SEK, you needed to have the stock in your portfolio before the ex-date on 6/19/2024.

When did Hansa Biopharma pay the last dividend?

The last dividend was paid out on 6/19/2024.

What was the dividend of Hansa Biopharma in the year 2023?

In the year 2023, Hansa Biopharma distributed 0 SEK as dividends.

In which currency does Hansa Biopharma pay out the dividend?

The dividends of Hansa Biopharma are distributed in SEK.